Interrad Medical and Eloquest Healthcare Partner to Expand U.S. Sales of SecurAcath

The partnership adds the revolutionary SecurAcath device to Eloquest Healthcare’s existing clinically oriented product offering

Interrad Medical, Inc., a privately-held medical device company, announces it has formed a strategic partnership with Eloquest Healthcare to accelerate the growth of SecurAcath sales in the U.S.

Interrad Medical notes the companies will provide hospitals and clinicians with the proven benefits of the SecurAcath to improve outcomes and reduce total medical expenses.

“We are excited to have the SecurAcath included with Eloquest’s complimentary, problem-solving products,” said Joe Goldberger, President and CEO of Interrad Medical, Inc. “Eloquest Healthcare is known for delivering innovative solutions that improve the standard of care with an emphasis on infection prevention and improved patient care, making them an excellent partner for Interrad Medical.”

“Securement-related catheter complications, including infections and dislodgements, are unacceptably high,” said Tim O’Halla, President and CEO of Eloquest Healthcare. “Current catheter securement methods of sutures and adhesive devices have shown to have higher complication rates than the SecurAcath. The innovative SecurAcath device is a perfect fit with our mission to improve the standard of care while reducing total cost of patient care.”

The SecurAcath is the only subcutaneous catheter securement device in the world. Just one SecurAcath lasts the life of the line and can significantly reduce risk of catheter-related infections, dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, and lower total cost of patient care. SecurAcath has more positive clinical evidence and guidance support than any other catheter securement device.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version